Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea for sickle cell disease.

S Davies1, A Olujohungbe

  • 1NHS Executive, Department of Health, 40 Eastbourne Terrace, London, UK, W2 3QR. sdaviet@doh.gov.uk

The Cochrane Database of Systematic Reviews
|June 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase II Study of Biodegradable Stents Plus Palliative Radiotherapy in Oesophageal Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

Development, behaviour and sensory processing in Marshall-Smith syndrome and Malan syndrome: phenotype comparison in two related syndromes.

Journal of intellectual disability research : JIDR·2020
Same author

High incidence of anti-cytokine autoantibodies in dogs with immune diseases suggests important immuno-regulatory functions.

Veterinary immunology and immunopathology·2019
Same author

"It's all in the history": A service evaluation of the quality of radiological requests in acute imaging.

Radiography (London, England : 1995)·2018
Same author

Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

Re: The accuracy of emergency abdominal CT in adult patients who present with non-traumatic abdominal pain: results of a UK national audit.

Clinical radiology·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Hydroxyurea therapy effectively reduces crises and complications in sickle cell disease patients. This treatment appears safe for severely affected adults, though further research is needed for other groups.

Area of Science:

  • Hematology
  • Pharmacology
  • Genetics

Background:

  • Sickle cell disease (SCD) is a prevalent inherited disorder causing significant morbidity and reduced lifespan worldwide.
  • Hydroxyurea, an oral chemotherapeutic agent, increases fetal hemoglobin (HbF) levels.
  • Elevated HbF is hypothesized to ameliorate the clinical manifestations of SCD.

Purpose of the Study:

  • To systematically evaluate the therapeutic effects of hydroxyurea in patients with sickle cell disease.
  • To assess hydroxyurea's efficacy across all SCD types, age groups, and clinical settings.
  • To determine the safety profile of hydroxyurea treatment in SCD management.

Main Methods:

  • Conducted a systematic review of randomized and quasi-randomized controlled trials.

Related Experiment Videos

  • Searched specialized registers and databases for relevant hemoglobinopathy studies up to November 2000.
  • Included trials comparing oral hydroxyurea (≥1 month) with placebo, standard care, or other interventions.

    • Main Results:

    • Two trials involving 324 adults and children met the inclusion criteria.
    • Analysis of one study (MSH trial) indicated hydroxyurea significantly reduced annual crisis rates, transfusion needs, and life-threatening complications, including acute chest syndrome, compared to placebo.
    • No serious adverse effects were reported in the included studies.

    Conclusions:

    • Hydroxyurea demonstrates effectiveness and safety in severely affected adult sickle cell disease patients over a two-year period.
    • Further research is warranted to establish hydroxyurea's role in pediatric populations and other sickle cell disease phenotypes.
    • Continued investigation is needed to explore hydroxyurea's utility for additional sickle cell-related conditions.